Health Canada's consultation on new additions to the Pathogens of Interest List

Antimicrobial resistant (AMR) infections are becoming more frequent and increasingly difficult to treat. As a result, AMR is now recognized as a growing public health threat in Canada and around the world. 

In support of the Pan-Canadian Framework on Antimicrobial Resistance and Antimicrobial Use, Health Canada is committed to facilitating regulatory approval of safe, effective, and high-quality innovative products that help address the issue of AMR. 

The purpose of this consultation is to request feedback from the public and stakeholders regarding the inclusion of additional antimicrobial resistant pathogens to the updated Pathogens of Interest List (the List). Pathogens on the List are deemed as pathogens creating the most urgent need for therapeutic drugs and/or diagnostic devices in Canada. 

Current Pathogens of Interest List

  • Acinetobacter spp. 

  • Burkholderia cepacia complex 

  • Campylobacter spp. 

  • Clostridioides difficile  

  • Enterobacteriaceae 

  • Enterococcus spp. 

  • Haemophilus influenzae 

  • Helicobacter pylori 

  • Mycobacterium tuberculosis (MTB) complex 

  • Neisseria gonorrhoeae 

  • Neisseria meningitidis 

  • Non-tuberculous mycobacteria species 

  • Pseudomonas spp. 

  • Salmonella spp.  

  • Shigella spp. 

  • Staphylococcus aureus 

  • Streptococcus agalactiae 

  • Streptococcus pneumoniae 

  • Streptococcus pyogenes 

  • Vibrio cholera 

Suggested Additions to the List

  • Candida spp. 

  • Cryptococcus spp. 

  • Aspergillus spp. 

To foster the development of innovative human therapeutic products to combat antimicrobial resistance (AMR), Health Canada has several regulatory measures that are available to expedite the review and approval process for drugs and diagnostic devices targeting pathogens on the List. Health Canada has updated the List to include fungal pathogens specific to the Canadian context. 

Your comments and suggestions are sought around the proposed update to the List, as well as on regulatory approaches to facilitate industry development for drugs and diagnostics targeting AMR pathogens: 

  • Should any of the proposed additional pathogens be removed from the update List and why? 

  • Should any other pathogens be added to the updated List and why?  

  • What new regulatory approaches or policy tools could be adopted that would facilitate greater access to safe, effective and high-quality therapies to help address the AMR issue? 

The input gathered through the consultation will be incorporated into the decision-making process of updating the List. 

Click here to learn more about the notice and consultation. 

Send your comments to practice@cshp.ca
by December 11, 2020. 

Note: SARS-CoV-2 (the novel coronavirus that causes COVID-19) and other viral, parasitic, and vector-borne pathogens are not within scope of this updated List.